Last edition
News about "Lilly Oncology "
FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL
Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.
Lilly Oncology | 04/12/2025 | By Dineshwori
Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth
Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.
Lilly Oncology | 07/11/2025 | By Dineshwori | 379
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
Lilly Oncology | 10/09/2025 | By Dineshwori | 108
Eli Lilly Announces Retirement of Anne White, Begins Search for Next Neuroscience Chief
Eli Lilly has announced that Anne White, Executive Vice President and President, Lilly Neuroscience, will retire from the company on December 31, 2025, after three decades of service.
Lilly Oncology | 21/08/2025 | By Dineshwori | 296
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy